Similarly, CDK4 overexpression aligns with increased proliferative capacity, and its role in lymphomagenesis is supported by studies demonstrating the sensitivity of CDK4/6-driven malignancies to pharmacologic inhibition and poor prognosis in DLBCL and other B-cell lymphomas (34). The gene discussed is CDK4; the disease is B-cell non-Hodgkin lymphoma.